Shenzhen Lifotronic Technology Co (688389) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shenzhen Lifotronic Technology Co (688389) has a cash flow conversion efficiency ratio of 0.025x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥53.10 Million ≈ $7.77 Million USD) by net assets (CN¥2.10 Billion ≈ $306.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shenzhen Lifotronic Technology Co - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Shenzhen Lifotronic Technology Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Shenzhen Lifotronic Technology Co total liabilities for a breakdown of total debt and financial obligations.
Shenzhen Lifotronic Technology Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Lifotronic Technology Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Glencore PLC
LSE:GLEN
|
0.033x |
|
Farmers National Banc Corp
NASDAQ:FMNB
|
0.040x |
|
Baticim Bati Anadolu Cimento Sanayi AS
IS:BTCIM
|
0.024x |
|
Guizhou Guihang Automotive Components Co Ltd
SHG:600523
|
-0.002x |
|
Jilin Expressway Co Ltd
SHG:601518
|
0.038x |
|
Dalian Demaishi Precision Technology Co.Ltd
SHE:301007
|
0.041x |
|
Bowhead Specialty Holdings Inc.
NYSE:BOW
|
0.266x |
|
Hubei Radio and Television Information Network Co Ltd
SHE:000665
|
0.009x |
Annual Cash Flow Conversion Efficiency for Shenzhen Lifotronic Technology Co (2016–2024)
The table below shows the annual cash flow conversion efficiency of Shenzhen Lifotronic Technology Co from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Shenzhen Lifotronic Technology Co (688389) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.05 Billion ≈ $299.89 Million |
CN¥296.47 Million ≈ $43.38 Million |
0.145x | -14.41% |
| 2023-12-31 | CN¥1.80 Billion ≈ $263.05 Million |
CN¥303.82 Million ≈ $44.46 Million |
0.169x | -10.21% |
| 2022-12-31 | CN¥1.44 Billion ≈ $211.23 Million |
CN¥271.71 Million ≈ $39.76 Million |
0.188x | +30.06% |
| 2021-12-31 | CN¥1.26 Billion ≈ $184.08 Million |
CN¥182.07 Million ≈ $26.64 Million |
0.145x | +21.33% |
| 2020-12-31 | CN¥1.14 Billion ≈ $167.34 Million |
CN¥136.42 Million ≈ $19.96 Million |
0.119x | +36.36% |
| 2019-12-31 | CN¥1.05 Billion ≈ $153.60 Million |
CN¥91.82 Million ≈ $13.44 Million |
0.087x | -27.94% |
| 2018-12-31 | CN¥668.39 Million ≈ $97.81 Million |
CN¥81.14 Million ≈ $11.87 Million |
0.121x | +102.24% |
| 2017-12-31 | CN¥587.25 Million ≈ $85.93 Million |
CN¥35.25 Million ≈ $5.16 Million |
0.060x | -20.50% |
| 2016-12-31 | CN¥370.82 Million ≈ $54.26 Million |
CN¥28.00 Million ≈ $4.10 Million |
0.076x | -- |
About Shenzhen Lifotronic Technology Co
Shenzhen Lifotronic Technology Co., Ltd. research, develops, manufactures, and markets medical devices for diagnostics, therapy, clinical medicine, skin, and human health related purposes in China. The company offers IVD products, such as HPLC, ECLIA, and hematology system; rapid test, molecular and POCT diagnostics. It also offers therapeutic products comprising respiratory and ICU, and wound ca… Read more